Production & Sales

Study says non-antibiotic drugs affect gut bacteria

Researchers from European Molecular Biology Laboratory (EMBL) have revealed that one in four drugs with human targets could affect the growth of bacteria in the human gut.

Biogen, AbbVie withdraw MS drug Zinbryta over safety concerns

Biogen and AbbVie are withdrawing their multiple sclerosis (MS) drug Zinbryta (daclizumab) from global market after reports of eight cases of serious brain inflammation.

Sanofi to buy hemophilia specialist Bioverativ for $11.6bn

French drugmaker Sanofi has agreed to acquire US-based biotechnology firm Bioverativ for about $11.6bn.

CGT Catapult to support CombiGene’s gene therapy for epilepsy

Cell and Gene Therapy (CGT) Catapult and Sweden-based CombiGene have signed an agreement to develop manufacturing process for novel gene therapy to treat epilepsy.

Regeneron forms consortium to accelerate sequencing of UK Biobank data

A new partnership between Regeneron Pharmaceuticals and five other drug manufacturers intends to accelerate the generation of genetic exome sequence data from the 500,000 participants of the UK Biobank.

Cardiff University researchers develop new tool to assess racemisation risk in drugs

Researchers at Cardiff University in the UK have developed a new method to test the likelihood of a drug turning into a potentially harmful version of itself when it enters the body.

ANI Pharmaceuticals buys four AstraZeneca NDAs

ANI Pharmaceuticals has acquired the new drug applications (NDAs) and US marketing rights for AstraZeneca’s Atacand, Atacand HCT, Arimidex, and Casodex for $46.5m.

Mallinckrodt to acquire Sucampo Pharmaceuticals for $1.2bn

Mallinckrodt has signed a deal to acquire US-based Sucampo Pharmaceuticals for about $1.2bn to add the latter’s constipation medication Amitiza (lubiprostone) and other commercial and development assets to its portfolio.

Drugmaker Teva to cut 14,000 jobs globally

Teva Pharmaceutical Industries said it will lay off 14,000 jobs globally as part of a two-year restructuring plan, aimed at boosting its business and financial performance.